Plus Therapeutics Announces Commercial Manufacturing Supply Agreement for Its Lead Investigational Drug (GlobeNewswire) - Sep 2, 2021 - "Plus Therapeutics...announced that it has entered into an agreement with RadioMedix, Inc. (RadioMedix) for the commercial production of the Company’s radiopharmaceuticals....'This strategic partnership substantially supports our efforts to have fully compliant 186RNL available by mid-2022 for a potential Phase 2/3 clinical study in adults with recurrent glioblastoma (GBM).”'"
Licensing / partnership • New P2/3 trial • Glioblastoma • Oncology
|